Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs

Drug Metabolism and Disposition

Volumn 26, Issue 6, 1998, Pages 528-535

  Andersson, Stig H G ^a   Lindgren, Anders ^a   Postlind, Hans ^a  

^a Pharmacia and Upjohn AB ^*

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; PNU 200577; PNU 200578; PNU 200579; TOLTERODINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOG; DRUG METABOLISM; DRUG OXIDATION; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; FEMALE; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; URGE INCONTINENCE; URINE INCONTINENCE;

ANIMALS; BENZHYDRYL COMPOUNDS; BIOTRANSFORMATION; CRESOLS; DOGS; FEMALE; MALE; MICE; MICROSOMES, LIVER; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031793033     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Andersson K-E (1988) Current concepts in the treatment of disorders of micturition. Drugs 35:477-498.
2. Brynne N, Stahl MMS, Hallén B, Edlund PO, Palmér L, Höglund P and Gabrielsson J (1997) Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 35:287-295.
3. Cardozo LD, Cooper D and Versi E (1987) Oxybutynin chloride in the management of idiopathic detrusor instability. Neurourol Urodyn 6:256-257.
4. Chiu SHL (1993) The use of in vitro metabolism studies in the understanding of new drugs. J Pharmacol Toxicol Methods 29:77-83.
5. Kankaanranta S and Påhlman I (1997) Interspecies relationship of pharmacokinetics of tolterodine and prediction in man using allometric scaling. ISSX Proc 11:122.
6. Lowry OH, Rosebrough NJ, Farr AL and Randall AJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
7. Mulder GJ (1982) Conjugation of phenols, in Metabolic Basis of Detoxication (Jacoby WB, Bend JR and Caldwell J eds) pp 248-264, Academic Press, New York.
8. Nilvebrant L, Hallén B and Larsson G (1997) Tolterodine: a new bladder selective muscarinic receptor antagonist: preclinical pharmacology and clinical data. Life Sci 60:1129-1136.
9. Norén B, Strömberg S, Ericsson Ö, Vangbo B, Gräils M, Widlund L and Lindeke B (1985) Biotransformation of terodiline. II. Disposition in the male rat: identification of metabolites in rat urine and rat liver microsomes by mass spectrometry. Acta Pharm Suec 22:131-146.
10. Postlind H, Lindgren A and Andersson SHG (1998) Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Disp 26:289-293.
11. Rodrigues AD (1994) Use of in vitro human metabolism studies in drug development. Biochem Pharmacol 48:2147-2156.
12. Shapiro BH, Agrawal AK and Pampori NA (1995) Gender differences in drug metabolism regulated by growth hormone. Int J Biochem Cell Biol 27:9-20.
13. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
14. Wein AJ, Longhurst PA and Levin RM (1994) Pharmacological treatment of voiding dysfunction, in Urodynamics: Principles, Practice and Application (Munday RA, Stephenson TP and Wein AJ eds) ed 2, pp 43-100, Churchill Livingstone, New York.
15. Yarker YE, Goa KL and Fitton A (1995) Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs Aging 6:243-262.